Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
6 E3 M. i7 { J$ CNOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 / H5 a1 P _; S# D- Z! N
+ Author Affiliations7 f4 C1 Q& t# b5 [
4 `" ]$ C6 S& M; \7 e1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan 8 b4 i% u" D4 o6 `. f: z- h* F
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan : F" f" c3 Z4 X% b3 Q% ^( r+ N+ E( D
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan ' o* n. |; ~" \3 o
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan 1 U7 W) P7 R2 e( }- T
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan 4 S& [: W: ?5 o9 U. [7 W
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan * f# t- h: ]+ X5 A* D" U
7Kinki University School of Medicine, Osaka 589-8511, Japan
4 q F2 Y4 b( [8Izumi Municipal Hospital, Osaka 594-0071, Japan ; g- ^2 ]' w/ J% s% `
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan / J: M& o8 ~/ M: F! c) `
Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp # r( Y, a+ O+ V& @
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. 0 y! N, w0 {4 M1 n1 q
+ R9 K- o+ _+ [ |